nsc-262266 and Lymphoma--Large-B-Cell--Diffuse

nsc-262266 has been researched along with Lymphoma--Large-B-Cell--Diffuse* in 1 studies

Other Studies

1 other study(ies) available for nsc-262266 and Lymphoma--Large-B-Cell--Diffuse

Article	Year
Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX. Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:3 We investigated the antitumoral activity of Dabis Maleate given on different dosage schedules and as continuous infusion in a murine reticular cell sarcoma M5076 (M5) and in a subline made resistant to cyclophosphamide and other nitrogen mustards (M5/CTX). The therapeutic index of Dabis Maleate was clearly better when the drug was given as a continuous 72-h infusion. Dabis Maleate appeared non-cross-resistant to cyclophosphamide and this property renders it interesting for further clinical development. Topics: Animals; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Division; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Quaternary Ammonium Compounds; Tumor Cells, Cultured	1992

Article

Year

Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX.

Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:3

We investigated the antitumoral activity of Dabis Maleate given on different dosage schedules and as continuous infusion in a murine reticular cell sarcoma M5076 (M5) and in a subline made resistant to cyclophosphamide and other nitrogen mustards (M5/CTX). The therapeutic index of Dabis Maleate was clearly better when the drug was given as a continuous 72-h infusion. Dabis Maleate appeared non-cross-resistant to cyclophosphamide and this property renders it interesting for further clinical development.

Topics: Animals; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Division; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Quaternary Ammonium Compounds; Tumor Cells, Cultured

1992